These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 8870824

  • 1. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II.
    Yamaguchi H, Ishiguro K, Uchida T, Takashima A, Lemere CA, Imahori K.
    Acta Neuropathol; 1996 Sep; 92(3):232-41. PubMed ID: 8870824
    [Abstract] [Full Text] [Related]

  • 2. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease.
    Imahori K, Uchida T.
    J Biochem; 1997 Feb; 121(2):179-88. PubMed ID: 9089387
    [Abstract] [Full Text] [Related]

  • 3. Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons.
    Takashima A, Honda T, Yasutake K, Michel G, Murayama O, Murayama M, Ishiguro K, Yamaguchi H.
    Neurosci Res; 1998 Aug; 31(4):317-23. PubMed ID: 9809590
    [Abstract] [Full Text] [Related]

  • 4. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration.
    Pei JJ, Grundke-Iqbal I, Iqbal K, Bogdanovic N, Winblad B, Cowburn RF.
    Brain Res; 1998 Jun 29; 797(2):267-77. PubMed ID: 9666145
    [Abstract] [Full Text] [Related]

  • 5. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells.
    Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, Gallo JM, Hanger D, Mulot S, Marquardt B, Stabel S.
    Curr Biol; 1994 Dec 01; 4(12):1077-86. PubMed ID: 7704571
    [Abstract] [Full Text] [Related]

  • 6. The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease.
    Leroy K, Boutajangout A, Authelet M, Woodgett JR, Anderton BH, Brion JP.
    Acta Neuropathol; 2002 Feb 01; 103(2):91-9. PubMed ID: 11810173
    [Abstract] [Full Text] [Related]

  • 7. Extracellular signal regulated kinases. Localization of protein and mRNA in the human hippocampal formation in Alzheimer's disease.
    Hyman BT, Elvhage TE, Reiter J.
    Am J Pathol; 1994 Mar 01; 144(3):565-72. PubMed ID: 8129042
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse.
    Planel E, Yasutake K, Fujita SC, Ishiguro K.
    J Biol Chem; 2001 Sep 07; 276(36):34298-306. PubMed ID: 11441005
    [Abstract] [Full Text] [Related]

  • 9. Cdk5 and munc-18/p67 co-localization in early stage neurofibrillary tangles-bearing neurons in Alzheimer type dementia brains.
    Takahashi M, Iseki E, Kosaka K.
    J Neurol Sci; 2000 Jan 01; 172(1):63-9. PubMed ID: 10620662
    [Abstract] [Full Text] [Related]

  • 10. Characterization of tau phosphorylation in glycogen synthase kinase-3beta and cyclin dependent kinase-5 activator (p23) transfected cells.
    Michel G, Mercken M, Murayama M, Noguchi K, Ishiguro K, Imahori K, Takashima A.
    Biochim Biophys Acta; 1998 Apr 10; 1380(2):177-82. PubMed ID: 9565682
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
    Wang JZ, Grundke-Iqbal I, Iqbal K.
    Eur J Neurosci; 2007 Jan 10; 25(1):59-68. PubMed ID: 17241267
    [Abstract] [Full Text] [Related]

  • 16. Phosphorylated protein kinases associated with neuronal and glial tau deposits in argyrophilic grain disease.
    Ferrer I, Barrachina M, Tolnay M, Rey MJ, Vidal N, Carmona M, Blanco R, Puig B.
    Brain Pathol; 2003 Jan 10; 13(1):62-78. PubMed ID: 12580546
    [Abstract] [Full Text] [Related]

  • 17. Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5.
    Sengupta A, Wu Q, Grundke-Iqbal I, Iqbal K, Singh TJ.
    Mol Cell Biochem; 1997 Feb 10; 167(1-2):99-105. PubMed ID: 9059986
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The retinoic acid and brain-derived neurotrophic factor differentiated SH-SY5Y cell line as a model for Alzheimer's disease-like tau phosphorylation.
    Jämsä A, Hasslund K, Cowburn RF, Bäckström A, Vasänge M.
    Biochem Biophys Res Commun; 2004 Jul 02; 319(3):993-1000. PubMed ID: 15184080
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.